• Miret Surgical

  Led · Series A · Apr 2014

  Miret Surgical is an Elmhurst, Illinois-based medical device startup developing proprietary laparoscopic surgical products. The company spun out of the Stanford University biodesign program and was founded by Kevin Chao MD, Tom Ruby PhD, Hattie Dong PhD, Christopher Pell MS, Bryan Duggan MS and Avi Roop. Its core products aim to reduce the invasiveness of standard surgical procedures while maintaining economic and procedural parity with the current standard of care. Miret intends to use the newly raised funds to continue product development. Prior to this financing, the company received grant support from the National Collegiate Inventors and Innovators Alliance and the Wallace H. Coulter Foundation. The company is advancing its laparoscopic offerings.

• Cloud Cruiser

  Participated · Series B · Jun 2012

  Cloud Cruiser, founded in 2010, has built a management platform that integrates with enterprise public and private cloud services to keep a running tally of usage and costs. The dashboard lets businesses set budgets, track spend across users and groups, provision new services, allocate them to individuals, and perform chargeback. It provides granular reporting and alerts when spending hits thresholds to help enterprises optimize cloud costs. The company reports more than 200 end customers and has recently struck partnerships with HP (for HP CloudSystem), Microsoft (for SystemCenter), and a reseller agreement with Seamless Technologies. Founders Dave Zabrowski and Greg Howard bring networking and chargeback experience from roles at HP, Neterion, CIMS Lab/IBM, and Wavepoint Ventures. Financially, Cloud Cruiser has raised $6M in a Series B and $7.6M in total since being founded. Cloud Cruiser is a San Francisco-based cloud computing startup focused on eliminating problems for cloud service providers and enterprises implementing virtualization and cloud computing infrastructure. The company says its work aims to enhance adoption of cloud computing through product offerings, but it remains in stealth mode. Cloud Cruiser closed a Series A financing led by Wavepoint Ventures with participation from existing angel investors. The announcement did not disclose the financing amount. Wavepoint Managing Director Peter Gardner said the firm targets capital-efficient businesses that solve high-priority problems in rapidly changing markets and views Cloud Cruiser as positioned to be a potential market leader. Founder and CEO Dave Zabrowski confirmed the company is in stealth and said product announcements will be made in the future.

• Second Genome

  Participated · Series A · Aug 2011

  Second Genome develops novel medicines by integrating microbiome and host biology through a drug-discovery platform that identifies novel targets and candidate drugs. Its data analysis techniques enable identification of microbes and microbial biomarkers that influence disease states. The company combines these discovery capabilities with drug development expertise to accelerate the rapid discovery of therapeutic options across a range of microbiome-related diseases. Second Genome intends to use the new funds to accelerate translation of its microbiome discoveries into a pipeline of clinical opportunities. Leadership cited in the report includes newly appointed CEO Glenn Nedwin, Ph.D., CSO Karim Dabbagh, Ph.D., and chairman and co-founder Corey Goodman, Ph.D. Second Genome leverages a microbiome discovery platform that combines genomics technologies, computational biology, and phenotypic screening to identify novel proteins, peptides, and metabolites that play causal roles in human disease and wellness. The company is led by CEO Peter DiLaura and is based in South San Francisco, CA. It closed a $42.6M Series B and has raised $59M in total to date. Second Genome plans to use the funds to expand its Microbiome Discovery Platform across indications tied to barrier function, insulin sensitivity, and immune regulation. The company will also advance the clinical investigation of SGM-1019, a small-molecule inhibitor targeting a microbiome-mediated pathway, through human proof-of-concept studies. The platform-driven approach supports discovery of molecules intended to address inflammation and pain in ulcerative colitis and other indications. Second Genome develops a Microbiome Signature Discovery Platform to identify and validate microbiome signatures rapidly and accurately. The company focuses on microbiome-based personalized medicine for gastrointestinal diseases and disorders, including IBS, IBD, antibiotic-associated diarrhea, and necrotizing enterocolitis. It partners with academic researchers and manufacturers of novel and existing therapies — including developers of probiotic, nutraceutical, and pharmaceutical products — to study therapy impacts on the gut microbiome and develop response signatures. The company intends to use the new funding to further develop its personalized medicine solutions for GI conditions. Second Genome was founded in 2009 as PhyloTech and is led by President and CEO Peter DiLaura and co-founder and Chairman Dr. Corey Goodman. The company is based in San Francisco, CA.

• PhyloTech

  Participated · Seed · Jul 2010

  PhyloTech develops technology that enables comprehensive, sensitive, and quantitative analysis of microbial communities using DNA from any sample type. Its offering is based on proprietary PhyloChip and related technology and includes end-to-end services: DNA amplification, labeling, fragmentation, hybridization, scanning, analysis, and web-accessible data reports. The company analyzes bacterial and archaeal taxa from any sample source for applications in human health, environmental damage assessment, bioremediation, recreational water quality, drinking water and food safety. PhyloTech raised $1.2m in a seed financing to start operations. The funds were provided by individual investors, including Seraph Group and Wavepoint Ventures. The company was founded in June 2009 and is based in San Francisco, CA.

No current team members are available.